Anagen effluvium
ICD-10 L65.1 is a billable code used to indicate a diagnosis of anagen effluvium.
Anagen effluvium is a type of hair loss characterized by the rapid shedding of hair during the anagen (growth) phase of the hair cycle. This condition can result from various factors, including chemotherapy, radiation therapy, autoimmune disorders, and severe stress. Clinically, patients may present with diffuse hair thinning or patchy hair loss, often noticeable within weeks of the triggering event. The scalp and hair follicles are primarily affected, with the hair shafts becoming weak and brittle, leading to increased shedding. Disease progression can vary; while some individuals may experience complete regrowth after the underlying cause is addressed, others may have prolonged hair loss. Diagnostic considerations include a thorough patient history, physical examination, and possibly a scalp biopsy to rule out other causes of hair loss. Laboratory tests may also be warranted to identify underlying systemic conditions contributing to hair loss. Early diagnosis and intervention are crucial to managing anagen effluvium effectively.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
L65.1 specifically covers anagen effluvium, which can be triggered by factors such as chemotherapy, radiation, autoimmune diseases, and severe stress. It is important to differentiate it from other types of hair loss, such as telogen effluvium or alopecia areata.
L65.1 should be used when hair loss is specifically due to the disruption of the anagen phase of the hair cycle. It is essential to use this code when the hair loss is rapid and linked to identifiable triggers, differentiating it from other hair loss conditions.
Documentation for L65.1 should include a detailed patient history, physical examination findings, and any relevant laboratory or imaging studies that support the diagnosis of anagen effluvium. Notes on the patient's treatment history, especially regarding chemotherapy or other triggering factors, are also crucial.
